Better Buy: Johnson & Johnson or AbbVie?
Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stocks. The companies are favored by income-oriented investors because each has raised its dividend for 50 years or more.
This is a pivotal year for both. Johnson & Johnson is expected to complete the spinoff of its consumer health segment later this year, perhaps the biggest shake-up in the company's history. AbbVie's Humira, for years the world's top-selling drug, will begin to face generic competition in the U.S. for the first time this year.
Johnson & Johnson is a little more diversified than AbbVie, even after the expected spinoff, because it is also a pharmaceutical company and a medtech company. AbbVie, while it is strictly a pharmaceutical company, offers more growth and a better dividend. Which is the better buy right now? Let's take a look.
Source Fool.com
